{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T07:05:52Z","timestamp":1778396752713,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.11.008","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T18:00:05Z","timestamp":1701108005000},"page":"e104-e111.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"given":"Sarah","family":"Goldman-Mazur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2023.11.008_bib0001","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2023.11.008_bib0002","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.clml.2023.11.008_bib0003","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","article-title":"Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing","volume":"26","author":"Agostino","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2023.11.008_bib0004","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00277-020-04060-z","article-title":"Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period","volume":"99","author":"Terpos","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.11.008_bib0005","series-title":"62nd ASH Annual Meeting and Exposition; Virtual Meeting","article-title":"Frits van Rhee. Late relapsing multiple myeloma \u2265 10 years after treatment on total therapy protocols are associated with good outcome","author":"Mohan","year":"2020"},{"issue":"8","key":"10.1016\/j.clml.2023.11.008_bib0006","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-020-00353-8","article-title":"Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma","volume":"10","author":"Paquin","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2023.11.008_bib0007","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.clml.2023.11.008_bib0008","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1158\/1078-0432.CCR-21-0134","article-title":"Development and validation of a simplified score to predict early relapse in newly diagnosed multiple myeloma in a pooled dataset of 2,190 patients","volume":"27","author":"Zaccaria","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.11.008_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7812\/TPP\/19.012","article-title":"Predictive factors for early relapse in multiple myeloma after autologous hematopoietic stem cell transplant","volume":"23","author":"Pourmoussa","year":"2019","journal-title":"Perm J"},{"issue":"7","key":"10.1016\/j.clml.2023.11.008_bib0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clml.2019.10.014","article-title":"Early relapse after autologous transplant is associated with very poor survival and identifies an ultra-high-risk group of patients with myeloma","volume":"20","author":"Kastritis","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.clml.2023.11.008_bib0011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma: an IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10068","key":"10.1016\/j.clml.2023.11.008_bib0012","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.clml.2023.11.008_bib0013","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2023.11.008_bib0014","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.008_bib0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10238-008-0169-8","article-title":"Long-term survival in multiple myeloma: a single-center experience","volume":"8","author":"Merchionne","year":"2008","journal-title":"Clin Exp Med"},{"issue":"4","key":"10.1016\/j.clml.2023.11.008_bib0016","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2141.1994.tb06745.x","article-title":"Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group","volume":"87","author":"Tsuchiya","year":"1994","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2023.11.008_bib0017","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1046\/j.1365-2141.1999.01462.x","article-title":"Long-term survival in multiple myeloma: a Finnish Leukaemia Group study","volume":"105","author":"Group","year":"1999","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.008_bib0018","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.bbmt.2019.12.484","article-title":"Long-term survival for myeloma after autologous stem cell transplantation","volume":"26","author":"Srour","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2023.11.008_bib0019","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2023.11.008_bib0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cam4.1283","article-title":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.clml.2023.11.008_bib0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ccr3.76","article-title":"Long-term survival in multiple myeloma","volume":"2","author":"Jo\u00e3o","year":"2014","journal-title":"Clin Case Rep"},{"issue":"11","key":"10.1016\/j.clml.2023.11.008_bib0022","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.11.008_bib0023","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.clml.2023.11.008_bib0024","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","article-title":"How I treat fragile myeloma patients","volume":"126","author":"Larocca","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.11.008_bib0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fonc.2020.00189","article-title":"Next-generation sequencing for clinical management of multiple myeloma: ready for prime time?","volume":"10","author":"Bolli","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.11.008_bib0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.11.008_bib0027","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bmt.2014.237","article-title":"Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents","volume":"50","author":"Jimenez-Zepeda","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2023.11.008_bib0028","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.16793","article-title":"Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma","volume":"193","author":"Bygrave","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.11.008_bib0029","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00576-3","article-title":"Genomic characterization of functional high-risk multiple myeloma patients","volume":"12","author":"Soekojo","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:39:59Z","timestamp":1708994399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021869"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.11.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}